Get the Stockscreener App
0.5319
2.87%
-0.0157
Century Therapeutics Inc stock is traded at $0.5319, with a volume of 710.57K.
It is down -2.87% in the last 24 hours and down -2.04% over the past month.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
See More
Previous Close:
$0.5476
Open:
$0.535
24h Volume:
710.57K
Relative Volume:
0.76
Market Cap:
$45.83M
Revenue:
$2.24M
Net Income/Loss:
$-136.67M
P/E Ratio:
-0.2323
EPS:
-2.29
Net Cash Flow:
$-102.08M
1W Performance:
-14.98%
1M Performance:
-2.04%
6M Performance:
-35.19%
1Y Performance:
-74.55%
1-Day Range:
$0.52
$0.569
1-Week Range:
$0.52
$0.6873
52-Week Range:
$0.3418
$2.16
Century Therapeutics Inc Stock (IPSC) Company Profile
Name
Century Therapeutics Inc
Sector
Industry
Phone
215-981-4000
Address
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
0.5319 | 47.18M | 2.24M | -136.67M | -102.08M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-27-22 | Initiated | Chardan Capital Markets | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| May-23-22 | Initiated | H.C. Wainwright | Buy |
| May-12-22 | Initiated | William Blair | Mkt Perform |
| Jul-13-21 | Initiated | BofA Securities | Buy |
| Jul-13-21 | Initiated | JP Morgan | Overweight |
| Jul-13-21 | Initiated | Piper Sandler | Overweight |
View All
Century Therapeutics Inc Stock (IPSC) Latest News
Comparing Praxsyn (OTCMKTS:PXYN) & Century Therapeutics (NASDAQ:IPSC) - Defense World
Century Therapeutics Inc. Stock Chart Analysis: Bullish or Bearish Pattern Forming - Newser
How hedge fund analytics apply to Century Therapeutics Inc. stockHigh Reward Investment Strategy for Beginners - Newser
Backtesting results for Century Therapeutics Inc. trading strategies7-Day Equity Return Range Forecast Model - Newser
Century Therapeutics (NASDAQ:IPSC) versus Biomerica (NASDAQ:BMRA) Financial Comparison - Defense World
What is Century Therapeutics Inc. company’s growth strategyMarket Forecast Recommendation With Low Risk - jammulinksnews.com
Will Century Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsAsset Safety Selection Using Quantitative Analysis - Newser
What makes Century Therapeutics Inc. stock price move sharplyAI Driven Swing Trade Forecasting Insight - Newser
Published on: 2025-07-30 19:14:22 - metal.it
Century Therapeutics (NASDAQ:IPSC) Shares Down 8.7% – Here’s Why - Defense World
Published on: 2025-07-29 18:11:16 - metal.it
Technical analysis overview for Century Therapeutics Inc. stockTop Stock Picks with Forecast Accuracy - Newser
What institutions are buying Century Therapeutics Inc. stock nowFree Weekly Growth Stock Entry Point Alerts - Newser
Layoff Tracker: Rocket Pharmaceuticals Cutting 30% of Workforce - BioSpace
How volatile is Century Therapeutics Inc. stock compared to the marketChart Pattern Updates With High Returns - jammulinksnews.com
Is Century Therapeutics Inc. stock overvalued or undervaluedBuild your wealth with consistent stock growth - jammulinksnews.com
Backtesting results for Century Therapeutics Inc. trading strategies Short Term Gain Strategy with AI Logic - Newser
What are the latest earnings results for Century Therapeutics Inc.Exceptional market performance - jammulinksnews.com
What are Century Therapeutics Inc. company’s key revenue driversInvest confidently with expert support - jammulinksnews.com
How does Century Therapeutics Inc. compare to its industry peersInvest smarter with daily market updates - jammulinksnews.com
How does Century Therapeutics Inc. generate profit in a changing economyUnlock expert insights for smarter investing - jammulinksnews.com
What catalysts could drive Century Therapeutics Inc. stock higher in 2025Market-leading profit generation - jammulinksnews.com
How Century Therapeutics Inc. stock performs during market volatilityProfessional Stock Screener - Newser
What drives Century Therapeutics Inc. stock priceHigh-yield portfolio picks - PrintWeekIndia
What analysts say about Century Therapeutics Inc. stockJaw-dropping returns - PrintWeekIndia
Century Therapeutics Inc. Stock Analysis and ForecastTremendous growth potential - Autocar Professional
Published on: 2025-07-22 15:49:56 - jammulinksnews.com
All You Need to Know About Century Therapeutics (IPSC) Rating Upgrade to Strong Buy - Yahoo Finance
Is Century Therapeutics Inc. a good long term investmentMarket-leading capital gains - jammulinksnews.com
Century Therapeutics Inc Stock (IPSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):